Small Trial of Alendronate Impact on the Reservoir of HIV (NCT07216794)
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial is designed to test the effects of alendronate (ALN) on people living with HIV who are already receiving antiretroviral therapy (ART). Participants are randomly assigned in a 2:1 ratio to either receive alendronate or a placebo, and neither the participants nor the researchers know who is receiving the actual treatment. The goal is to see if alendronate can reduce the size and activity of the HIV-1 reservoir in these individuals.
Who can join: Review the eligibility criteria below.
Location: University of California, San Francisco HIV/AIDS (Site ID: 801) — San Francisco, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University of California, San Francisco HIV/AIDS (Site ID: 801) — San Francisco, California
- University of Colorado Hospital (Site ID: 6101) — Aurora, Colorado
- Chapel Hill (Site ID: 3201) — Chapel Hill, North Carolina
- Ohio State University (Site ID: 2301) — Columbus, Ohio
- University of Pittsburgh (Site ID: 1001) — Pittsburgh, Pennsylvania
📞 Contact the Study Coordinator
Phone: (919) 904-9668
Email: nataliasorsar@gwu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HIV
- CD4 CAR+ ZFN-modified T Cells in HIV Therapy — Philadelphia, Pennsylvania
- Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP — Orlando, Florida
- Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients — Duarte, California
- Urban Gardening and Peer Nutritional Counseling for People With HIV and Food Insecurity — Azua,
- Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. — Birmingham, Alabama
- Wellness, Intervention Strategies and HIV Care — Oakland, California
Explore by condition: All HIV clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.